Effect of leptin replacement on PCSK9 in ob/ob mice and female lipodystrophic patients

Endocrinology

Volumn 157, Issue 4, 2016, Pages 1421-1429

  Levenson, Amy E ^a   Haas, Mary E ^a   Miao, Ji ^a   Brown, Rebecca J ^b   De Ferranti, Sarah D ^a   Muniyappa, Ranganath ^b   Biddinger, Sudha B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DNA DIRECTED DNA POLYMERASE ALPHA; FRUCTOSE BISPHOSPHATE; GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METRELEPTIN; NUCLEAR FACTOR I; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RECOMBINANT LEPTIN; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LEPTIN; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPODYSTROPHY; MALE; MOUSE; NONHUMAN; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; OSMOTIC PUMP; PCSK9 MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RNA ISOLATION; SEX DIFFERENCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; LIVER; METABOLISM; MOUSE MUTANT; OBESITY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ANIMALS; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; LEPTIN; LIPODYSTROPHY; LIVER; MALE; MICE, OBESE; OBESITY; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; SEX FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84964426627     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1624     Document Type: Article

References (54)

1. Park HK, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism. 2015;64(1): 24-34.
2. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220-1234.
3. Prieur X, Le May C, Magré J, Cariou B. Congenital lipodystrophies and dyslipidemia. Curr Atheroscler Rep. 2014;16(9):437.
4. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 17(6):922-932.
5. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53(1):27-35.
6. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093-1103.
7. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54(7):1994-2002.
8. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345-1350.
9. Asilmaz E, Cohen P, Miyazaki M, et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest. 2004;113(3):414-424.
10. SlyperAH.Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA. 1994;272(4):305-308.
11. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2): 154-156.
12. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor andLDLcholesterol. J BiolChem. 2004; 279(47):48865-48875.
13. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78(3):410-422.
14. Cohen JC, Boerwinkle E, MosleyTHJr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272.
15. Shantha G, Robinson JG. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. Clin Pharmacol Ther. 2016;99(1):59-71.
16. Dirlam KA, Gretch DG, LaCount DJ, Sturley SL, Attie AD. Expression and characterization of a truncated, soluble, low-density lipoprotein receptor. Protein Expr Purif. 1996;8(4):489-500.
17. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24(8):1454-1459.
18. Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008;7:22.
19. Lakoski SG, Xu F, Vega GL, et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010;95(2):800-809.
20. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24(3):539-548.
21. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325(5936):100-104.
22. Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 2006;281(10):6211-6218.
23. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Steroldependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399-409.
24. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1β plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284(42):28885-28895.
25. Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1β and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486-1495.
26. Muniyappa R, Brown RJ, Mari A, et al. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy. Diabetes Care. 2014;37(4):1101-1107.
27. Joseph J, Shamburek RD, Cochran EK, Gorden P, Brown RJ. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J Clin Endocrinol Metab. 2014;99(9):E1676-E1680.
28. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism. 2007;56(4):508-516.
29. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928-933.
30. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279(48): 50630-50638.
31. Ai D, Chen C, Han S, et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest. 2012;122(4):1262-1270.
32. Han S, Liang CP, Westerterp M, et al. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest. 2009;119(4):1029-1041.
33. Miao J, Manthena PV, Haas ME, et al. Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9. Arterioscler Thromb Vasc Biol. 2015;35(7):1589-1596.
34. Lundåsen T, Liao W, Angelin B, Rudling M. Leptin induces the hepatic high density lipoprotein receptor scavenger receptor B type I (SR-BI) but not cholesterol 7 α-hydroxylase (Cyp7a1) in leptindeficient (ob/ob) mice. J Biol Chem. 2003;278(44):43224-43228.
35. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA. 1999;96(20):11041-11048.
36. Goedeke L, Rotllan N, Canfrán-Duque A, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015;21(11):1280-1289.
37. Singh AB, Li H, Kan CF, Dong B, NicollsMR,Liu J. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3′ untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler Thromb Vasc Biol. 2014;34(1):8-16.
38. Hasty AH, Shimano H, Osuga J, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001; 276(40):37402-37408.
39. Bryson JM, Phuyal JL, Swan V, Caterson ID. Leptin has acute effects on glucose and lipid metabolism in both lean and gold thioglucoseobese mice. Am J Physiol Endocrinol Metab. 1999;277(3):E417-E422.
40. Minokoshi Y, Kim YB, PeroniOD,et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339-343.
41. Silver DL,WangN, TallAR.DefectiveHDLparticle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J Clin Invest. 2000;105(2):151-159.
42. Ohkura N, Oishi K, Atsumi G. Blood coagulation and metabolic profiles in middle-aged male and female ob/ob mice. Blood Coagul Fibrinolysis. 2015;26(5):522-526.
43. Nishina PM, Lowe S, Wang J, Paigen B. Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism. 1994;43(5):549-553.
44. Gao Q, Horvath TL. Cross-talk between estrogen and leptin signaling in the hypothalamus. Am J Physiol Endocrinol Metab. 2008; 294(5):E817-E826.
45. Knopp RH, Paramsothy P, Retzlaff BM, et al. Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Cardiol Rep. 2006;8(6):452-459.
46. Ghosh M, Gälman C, Rudling M, Angelin B. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res. 2015;56(2):463-469.
47. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537-2543.
48. Persson L, Henriksson P, Westerlund E, Hovatta O, Angelin B, Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol. 2012;32(3):810-814.
49. Starr AE, Lemieux V, Noad J, et al. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in lowdensity lipoprotein receptor levels in human hepatic HuH7 cells. FEBS J. 2015;282(14):2682-2696.
50. Roubtsova A, Chamberland A, Marcinkiewicz J, et al. PCSK9 deficiency unmasks a sex-and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. J Lipid Res. 2015;56(11): 2133-2142.
51. Patni N, Garg A. Congenital generalized lipodystrophies-new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015;11(9): 522-534.
52. Garg A. Clinical review: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313-3325.
53. Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5): 1802-1810.
54. Kissebah AH, Alfarsi S, Adams PW, Wynn V. The metabolic fate of plasma lipoproteins in normal subjects and in patients with insulin resistance and endogenous hypertriglyceridaemia. Diabetologia. 1976;12(5):501-509.